Version 1
: Received: 3 April 2024 / Approved: 3 April 2024 / Online: 3 April 2024 (16:31:38 CEST)
How to cite:
Gonçalves, J.M.; Carvalho, B.; Tuna, R.; Polónia, P.; Linhares, P. Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients. Preprints2024, 2024040320. https://doi.org/10.20944/preprints202404.0320.v1
Gonçalves, J.M.; Carvalho, B.; Tuna, R.; Polónia, P.; Linhares, P. Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients. Preprints 2024, 2024040320. https://doi.org/10.20944/preprints202404.0320.v1
Gonçalves, J.M.; Carvalho, B.; Tuna, R.; Polónia, P.; Linhares, P. Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients. Preprints2024, 2024040320. https://doi.org/10.20944/preprints202404.0320.v1
APA Style
Gonçalves, J.M., Carvalho, B., Tuna, R., Polónia, P., & Linhares, P. (2024). Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients. Preprints. https://doi.org/10.20944/preprints202404.0320.v1
Chicago/Turabian Style
Gonçalves, J.M., Patricia Polónia and Paulo Linhares. 2024 "Sequential Evaluation of Hematology Markers as a Prognostic Factor in Glioblastoma Patients" Preprints. https://doi.org/10.20944/preprints202404.0320.v1
Abstract
In our study, we investigated the prognostic significance of hematological markers—NLR (Neutrophil-to-Lymphocyte Ratio), PLR (Platelet-to-Lymphocyte Ratio), and RDW-CV (Red Blood Cell Distribution Width - Coefficient of Variation)—in 117 glioblastoma patients. Data collected from January 2016 to December 2018 included demographics, clinical scores, and treatment regimens. Unlike previous research, which often examined these markers solely before surgery, our unique approach analyzed them at multiple stages: preoperative, postoperative, and before adjuvant therapies. We correlated these markers with overall survival (OS) and progression-free survival (PFS) using statistical tools, including ANOVA, Cox regression, and Kaplan-Meier survival analyses, employing SPSS version 29.0. Our findings revealed notable variations in NLR, PLR, and RDW-CV across different treatment stages. NLR and PLR decreased after surgery, with some stabilization post-STUPP phase (NLR: p=0.007, η2p=0.06; PLR: p=0.001, η2p=0.23), while RDW-CV increased post-surgery and during subsequent treatments (RDW-CV: p < 0.001, η2p=0.67). Importantly, we observed significant differences between the preoperative phase and other treatment phases. Additionally, higher NLR and RDW-CV at the second-line treatment and disease progression were associated with an increased risk of death (NLR at 2nd line: HR=1.03, p=0.029; RDW-CV at progression: HR=1.14, p=0.004). We proposed specific marker cutoffs that demonstrated significant associations with survival outcomes when applied to Kaplan-Meier survival curves (NLR at 2nd line < 5: p<0.017; RDW-CV at progression < 15: p=0.007). Elevated NLR and RDW-CV at later treatment stages correlated with poorer OS and PFS. No significant preoperative differences were detected. These biomarkers may serve as non-invasive tools for glioblastoma management.
Keywords
Glioblastoma; Hematological markers; Non-invasive biomarkers; Neutrophil-to-Lymphocyte Ratio (NLR); Platelet-to-Lymphocyte Ratio (PLR); Red Blood Cell Distribution Width (RDW-CV)
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
